News

For the third year, the Society of Nuclear Medicine and Molecular Imaging's Patient Advocacy Advisory Board developed a Patient Program to address key topics of interest to the patient and patient advocacy community.  These presentations were given at the SNMMI Patient Education Day, June 9th in Vancouver, BC.

Over 500 medical professionals attended the 2nd World Congress on Ga68 and Radiotherapy that was held in Chandigarh India, February 28 - March 2, 2013.  Over the course of 3 days over 100 presentations and posters were presented reflecting the current usage of Ga68 and PRRT around the world as well as new and exciting development that have taken place since the 1st world congress in 2011.  The abstracts for this conference as well as for the 22nd Singapore Nuclear Review are available free of charge at the World Journal of Nuclear Medicine.  

This congress saw advancement in using GA68 as a tracer for infection and inflammation as well as for receptor positive forms of breast and prostate cancer in addition to its use as a

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open in the US and Europe and is actively recruiting patients.

The study is seeking 200 patients at over 50 institutions in a randomized trial - those that are randomized to the non-PRRT arm will receive LAR 60 (high dose).

To learn more about the trial, please visit clinicaltrials.gov.

While we were in Chandigarh, India for the 2nd World Congress on Ga68 we were abole to film the following press conference with Professors Baum, Shultz and Singh about the importance of the Congress. Please make sure to click the read more button to see all 3 talks.

Patient knowledge and understanding of radiation from diagnostic imaging is lacking, according to a research letter published online Dec. 31, 2012, in JAMA Internal Medicine . More than half of patients surveyed heard nothing in the media about radiation from medical imaging, and many of those aware of radiation exposure substantially underestimated dose.

Read more at healthimaging.com

 


We at PRRTinfo.org are working with the Society of Nuclear Medicine and Molecular Imaging to provide

Miami Beach, Fla. – The Society of Nuclear Medicine's (SNM) 2012 Image of the Year illustrates the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that do not respond to beta therapy. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNM's 2012 Annual Meeting in Miami Beach, Fla. To view the complete article, click here.

A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients, say researchers at the Society of Nuclear Medicine's 59th Annual Meeting.

Results of the study indicated that PET/CT and Ga-68 DOTATATE was highly sensitive and specific for assessing neuroendocrine tumors and changed thecourse of treatment for a large number of patients. Prior to imaging, more than half of the

Subcategories